<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Des Devel Ther</journal-id><journal-id journal-id-type="iso-abbrev">Drug Des Devel Ther</journal-id><journal-id journal-id-type="publisher-id">Drug Design, Development and Therapy</journal-id><journal-title-group><journal-title>Drug Design, Development and Therapy</journal-title></journal-title-group><issn pub-type="epub">1177-8881</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.2147/DDDT.S72797</article-id><article-id pub-id-type="publisher-id">dddt-8-2311</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Choosing preclinical study models of diabetic retinopathy: key problems for consideration</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mi</surname><given-names>Xue-Song</given-names></name><xref ref-type="aff" rid="af1-dddt-8-2311">1</xref><xref ref-type="aff" rid="af2-dddt-8-2311">2</xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Ti-Fei</given-names></name><xref ref-type="aff" rid="af3-dddt-8-2311">3</xref><xref ref-type="aff" rid="af4-dddt-8-2311">4</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="af1-dddt-8-2311">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhong</surname><given-names>Jing-Xiang</given-names></name><xref ref-type="aff" rid="af1-dddt-8-2311">1</xref><xref ref-type="corresp" rid="c2-dddt-8-2311"/></contrib><contrib contrib-type="author"><name><surname>So</surname><given-names>Kwok-Fai</given-names></name><xref ref-type="aff" rid="af4-dddt-8-2311">4</xref><xref ref-type="aff" rid="af5-dddt-8-2311">5</xref><xref ref-type="corresp" rid="c1-dddt-8-2311"/></contrib></contrib-group><aff id="af1-dddt-8-2311"><label>1</label>Department of Ophthalmology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People&#x02019;s Republic of China</aff><aff id="af2-dddt-8-2311"><label>2</label>Department of Anatomy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People&#x02019;s Republic of China</aff><aff id="af3-dddt-8-2311"><label>3</label>School of Psychology, Nanjing Normal University, Nanjing, People&#x02019;s Republic of China</aff><aff id="af4-dddt-8-2311"><label>4</label>Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong</aff><aff id="af5-dddt-8-2311"><label>5</label>Guangdong-Hongkong-Macau Institute of Central Nervous System, Jinan University, Guangzhou, People&#x02019;s Republic of China</aff><author-notes><corresp id="c1-dddt-8-2311">Correspondence: Kwok-Fai So, Guangdong-Hongkong-Macau Institute of Central Nervous System Regeneration, Jinan university, Huang Pu Road West 601, Guangzhou, 510632, People&#x02019;s Republic of China, Email <email>hrmaskf@hku.hk</email></corresp><corresp id="c2-dddt-8-2311">Jing-Xiang Zhong, Department of Ophthalmology, First Affiliated Hospital of Jinan University, Guangzhou, 510632, People&#x02019;s Republic of China, Email <email>zjx85221206@163.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>18</day><month>11</month><year>2014</year></pub-date><volume>8</volume><fpage>2311</fpage><lpage>2319</lpage><permissions><copyright-statement>&#x000a9; 2014 Mi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p>Diabetic retinopathy (DR) is the most common complication of diabetes mellitus in the eye. Although the clinical treatment for DR has already developed to a relative high level, there are still many urgent problems that need to be investigated in clinical and basic science. Currently, many in vivo animal models and in vitro culture systems have been applied to solve these problems. Many approaches have also been used to establish different DR models. However, till now, there has not been a single study model that can clearly and exactly mimic the developmental process of the human DR. Choosing the suitable model is important, not only for achieving our research goals smoothly, but also, to better match with different experimental proposals in the study. In this review, key problems for consideration in choosing study models of DR are discussed. These problems relate to clinical relevance, different approaches for establishing models, and choice of different species of animals as well as of the specific in vitro culture systems. Attending to these considerations will deepen the understanding on current study models and optimize the experimental design for the final goal of preventing DR.</p></abstract><kwd-group><title>Keywords</title><kwd>animal model</kwd><kwd>in vitro culture</kwd><kwd>ex vivo culture</kwd><kwd>neurovascular dysfunction</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The worldwide incidence of diabetes is rising quickly. Studies have shown that after 10 years of diabetes, nearly 50% of type 2 and 70% of type 1 diabetic patients will develop diabetic retinopathy (DR).<xref rid="b1-dddt-8-2311" ref-type="bibr">1</xref> As a leading cause of blindness in eye diseases, DR drives much attention, on the part of clinical and basic researchers, to the investigation of its mechanism and prevention. However, the pathogenesis of DR is complicated, so validated study models are needed to deepen our understanding of the disease mechanisms and for trying new approaches for early screening and therapeutic intervention.</p><p>DR is a common clinical condition. As to study models for DR, there are several different species of animal models, from tiny zebrafish to monkeys, and in vitro culture systems for retinal blood vessel assay, using human or nonhuman tissues. All of these models are aimed at mimicking the clinical course of DR, while each has its limitation in matching the full features of the human disease. Previously, there have been some reviews describing animal models of DR in great detail.<xref rid="b2-dddt-8-2311" ref-type="bibr">2</xref>&#x02013;<xref rid="b6-dddt-8-2311" ref-type="bibr">6</xref> In addition, there are other reviews focusing on angiogenesis models in vivo<xref rid="b7-dddt-8-2311" ref-type="bibr">7</xref> and in vitro.<xref rid="b8-dddt-8-2311" ref-type="bibr">8</xref> However, when a researcher is faced with choosing the study model for different purposes, there are many key problems to consider in advance.</p><p>In this review, a summary of the most common and important problems for consideration on the selection of appropriate study models of DR is provided. The features and challenges of clinical DR that should be considered in preclinical studies are discussed first. Then, the current research focuses in clinical and basic science are summarized, for researchers to consider and compare with their own experimental goals. Finally, the popular modeling approaches in common animal species, together with their advantages and limitations, are summarized. These considerations will help researchers to select the appropriate candidate when facing multiple choices of study models.</p></sec><sec><title>Clinical considerations</title><sec sec-type="intro"><title>Characteristics of human DR</title><p>Clinically, DR is mainly classified in two groups, nonproliferative DR (NPDR) and proliferative DR (PDR). PDR is judged by the presence of retinal neovascularization,<xref rid="b9-dddt-8-2311" ref-type="bibr">9</xref> which is usually confirmed with fluorescence fundus angiography imaging. PDR is the more advanced stage of DR. In PDR, proliferating neovasculature contributes to severe complications, eg, vitreous hemorrhage, retinal scars, and tractional retinal detachment, all of which often need vitreoretinal surgery. However, the endpoint of PDR is variable, and irreversible vision loss is attributed to retinal structure damage and layer thinning. Thus, the Early Treatment of Diabetes Retinopathy Study (ETDRS) has staged NPDR with mild, moderate, and severe grades, aimed to screen risk factors and to detect the earlier stages of DR for nonsurgical treatment, eg, retinal photocoagulation or antiangiogenic therapy.<xref rid="b10-dddt-8-2311" ref-type="bibr">10</xref>,<xref rid="b11-dddt-8-2311" ref-type="bibr">11</xref></p><p>Histologically, retinal vascular lesions are considered to be the hallmark and the grading criterion of DR. The first visible alteration in retinal vasculature is the formation of microaneurysms. The further changes are intraretinal focal hemorrhage, venous beading, and intraretinal microvascular abnormalities (IRMAs) showing with microvascular torsion and regional capillary nonperfusion on fluorescence fundus angiography imaging. IRMA is associated with &#x0201c;cotton wool&#x0201d; spots observed with funduscopy, which are focal infarcts of nerve fibers in essence. Following the progression of vascular damage, diabetic macular edema appears, which is one of the major causes of vision loss in DR, linking with lesions at the blood&#x02013;retinal barrier.<xref rid="b12-dddt-8-2311" ref-type="bibr">12</xref>,<xref rid="b13-dddt-8-2311" ref-type="bibr">13</xref></p></sec><sec><title>Clinical challenges</title><p>A current clinical challenge for consideration in diagnosis and prevention is the screening for risk factors that contribute to retinal vascular abnormality, for eg, studies of ocular blood flow;<xref rid="b14-dddt-8-2311" ref-type="bibr">14</xref>,<xref rid="b15-dddt-8-2311" ref-type="bibr">15</xref> biomarkers detected in body fluids, like advanced glycation end products (AGEs); interleukins; and tumor necrosis factor-&#x003b1; (TNF-&#x003b1;).<xref rid="b16-dddt-8-2311" ref-type="bibr">16</xref>,<xref rid="b17-dddt-8-2311" ref-type="bibr">17</xref></p><p>As to nonsurgical therapeutic investigations, the focus has been on treating diabetic macular edema and antiangiogenesis, and on vascular cell protection to inhibit neovascularization, for eg, with vascular endothelial growth factor (VEGF) inhibitor<xref rid="b18-dddt-8-2311" ref-type="bibr">18</xref> or other potential ocular-delivered drugs.<xref rid="b19-dddt-8-2311" ref-type="bibr">19</xref>&#x02013;<xref rid="b22-dddt-8-2311" ref-type="bibr">22</xref> Recently, anti-VEGF has become one of most important discoveries to treat neovascularization clinically. However, limitations to anti-VEGF therapies also exist, eg, resistance, systemic side effects with local use, and non-VEGF-related vascular proliferative mechanisms.<xref rid="b18-dddt-8-2311" ref-type="bibr">18</xref>&#x02013;<xref rid="b22-dddt-8-2311" ref-type="bibr">22</xref> Indeed, other than VEGF, more and more potentially angiogenic factors have been discovered, such as insulin-like growth factor 1 (IGF-1),<xref rid="b23-dddt-8-2311" ref-type="bibr">23</xref> platelet-derived growth factor B (PDGF-B), erythropoietin (EPO), angiopoietin 2,<xref rid="b24-dddt-8-2311" ref-type="bibr">24</xref> interleukin 8 (IL-8), etc.<xref rid="b25-dddt-8-2311" ref-type="bibr">25</xref> Antioxidants, eg, alpha-lipoic acid (ALA), are other potential drugs that prevent micro- and macrovascular damage, by normalizing pathways downstream of mitochondrial overproduction of reactive oxygen species, and preserve pericyte coverage of retinal capillaries.<xref rid="b26-dddt-8-2311" ref-type="bibr">26</xref>,<xref rid="b27-dddt-8-2311" ref-type="bibr">27</xref></p><p>As to surgical aspects, treatment advances are largely dependent on development of new instruments for the goal of perfecting results of vitreoretinal surgery. However, when DR is advanced to the proliferative stage, surgical effect is limited to the severe damage of retinal neurovascular structure.<xref rid="b28-dddt-8-2311" ref-type="bibr">28</xref>,<xref rid="b29-dddt-8-2311" ref-type="bibr">29</xref></p><p>Thus, more and more preclinical trials need to use different in vivo animal models or in vitro vascular assays to understand the mechanisms and to find potential treatment to prevent human DR.</p></sec></sec><sec><title>Choices of study model in DR</title><sec><title>Principle of choice: Research goal is the basic consideration</title><p>Understanding of the mechanism of DR is complicated by the complexity of the retinal structure. The retina contains multiple cell components and structure, and when exposed to the stress of hyperglycemia, not only blood vessels but also, retinal neurons and glial cells will all be challenged by the insult. The concept of the neurovascular unit is a kind of simplified understanding of the crosstalk between the retinal blood vessel and other cells around it.<xref rid="b30-dddt-8-2311" ref-type="bibr">30</xref> From the view of a neurovascular hypothesis in DR, conditions of hyperglycemia induce vascular damage, thereafter destroying the microenvironment and the crosstalk between endothelial cells/pericytes and neurons, endothelial cells/pericytes and retinal glial cells, as well as neurons and glial cells, finally leading to vascular proliferation, glial proliferation, and neural degeneration (<xref ref-type="fig" rid="f1-dddt-8-2311">Figure 1</xref>).</p><p>Previously, the focus was on establishing various animal models of DR, and there were many classic studies investigating morphological damage to the retinal vasculature and comparing this to clinical features found in human DR. Studies have shown that one of the earliest histological changes of DR is thickening of the capillary basement membrane.<xref rid="b31-dddt-8-2311" ref-type="bibr">31</xref> Dysfunction of endothelial cells and pericytes, and thereafter cell loss, are also early phenomena, which could be responsible for the acellular capillary formation.<xref rid="b4-dddt-8-2311" ref-type="bibr">4</xref> It is believed that the formation of microaneurysms, the hallmark alteration of human DR, are attributed to the loss of pericytes.<xref rid="b32-dddt-8-2311" ref-type="bibr">32</xref> Cotton wool spots are linked with focal IRMAs.<xref rid="b33-dddt-8-2311" ref-type="bibr">33</xref></p><p>Therefore, we summarized the current research areas and categorized them with respect to the different stages of development of DR and according to their different goals. At different stages of NPDR and PDR, there have been different points of focus, for eg, in NPDR, the blood vessel-related research focuses on early biomarkers to detect vascular dysfunction,<xref rid="b34-dddt-8-2311" ref-type="bibr">34</xref> the mechanisms for how hyperglycemia induces vascular damage,<xref rid="b35-dddt-8-2311" ref-type="bibr">35</xref> and potential treatment to protect endothelial cells or pericytes from dysfunction or loss.<xref rid="b22-dddt-8-2311" ref-type="bibr">22</xref> Neuron-related research has focused on early detection of neural degeneration by electrophysiological methods,<xref rid="b36-dddt-8-2311" ref-type="bibr">36</xref>,<xref rid="b37-dddt-8-2311" ref-type="bibr">37</xref> and neuroprotection.<xref rid="b38-dddt-8-2311" ref-type="bibr">38</xref>,<xref rid="b39-dddt-8-2311" ref-type="bibr">39</xref> Glial cell-related research focuses on the response of retinal astrocytes and M&#x000fc;ller cells.<xref rid="b39-dddt-8-2311" ref-type="bibr">39</xref> Microenvironment damage&#x02013;related research directions include cytokines and the mechanisms of inflammation, as well as immune-associated mechanisms, etc.<xref rid="b40-dddt-8-2311" ref-type="bibr">40</xref> As to preventing PDR, the current research goals relate to potential therapies for inhibiting or treating the complications of neovascularization, eg, anti-VEGF, which was mentioned above. Thus, after clarifying the goal of investigation and the related stage in DR, researchers can pay attention to the choices for different approaches and study models.</p></sec><sec sec-type="methods"><title>Different choices to establish study model of DR</title><p>Currently, in the establishment of animal models for DR, there are mainly three approaches: 1) inducing experimental hyperglycemia, 2) using animals with spontaneous diabetes mellitus, and 3) inducing retinal angiogenesis without diabetes mellitus.</p><p>As to the approach of experimental hyperglycemia induction, this mainly includes: a) pharmacological methods, for eg, intraperitoneal injection of streptozotocin (STZ)<xref rid="b41-dddt-8-2311" ref-type="bibr">41</xref>&#x02013;<xref rid="b45-dddt-8-2311" ref-type="bibr">45</xref> or alloxan;<xref rid="b46-dddt-8-2311" ref-type="bibr">46</xref> b) diet methods, such as feeding a high-galactose diet;<xref rid="b46-dddt-8-2311" ref-type="bibr">46</xref> and c) surgical method, for eg, Pancreatectomy.<xref rid="b47-dddt-8-2311" ref-type="bibr">47</xref></p><list list-type="simple"><list-item><label>a)</label><p>Regarding induction of pharmacological hyperglycemia, intraperitoneal injection using STZ is the classic and most popular approach to establish diabetic animal models. The mechanism is that STZ can kill pancreatic &#x003b2; cells by its toxicity. Following the hyperglycemia, the animal will develop DR. Compared with the other methods listed above, STZ injection is time-saving and efficient and has been used widely in rodents and large animals, for eg, rabbits, cats, dogs, pigs, and monkeys. The standard modeling protocol that has been established in mice was suggested by the Animal Models of Diabetic Complications Consortium.<xref rid="b48-dddt-8-2311" ref-type="bibr">48</xref> It has been reported that the STZ-induced model could demonstrate NPDR, however, rarely forming microaneurysms.<xref rid="b49-dddt-8-2311" ref-type="bibr">49</xref> In addition, only a few studies reported the formation of focal neovascularization.<xref rid="b50-dddt-8-2311" ref-type="bibr">50</xref> Alloxan is another drug used to induce hyperglycemia. However, compared with STZ, the alloxan-induced model has needed longer time to demonstrate a milder level of pathological change of DR &#x02013; reportedly 3 months in mice<xref rid="b46-dddt-8-2311" ref-type="bibr">46</xref> and 12 months in rats.<xref rid="b51-dddt-8-2311" ref-type="bibr">51</xref></p></list-item><list-item><label>b)</label><p>The high galactose-diet feeding method can be used in rodents and other large animals. Compared with the STZ method, it is time-consuming. However, it is suitable for zebrafish, by just directly elevating the concentration of glucose in the fishpond.<xref rid="b52-dddt-8-2311" ref-type="bibr">52</xref></p></list-item><list-item><label>c)</label><p>Surgical methods, like pancreatectomy, can be used in large animals, such as cats,<xref rid="b47-dddt-8-2311" ref-type="bibr">47</xref> pigs,<xref rid="b53-dddt-8-2311" ref-type="bibr">53</xref> and monkeys.<xref rid="b54-dddt-8-2311" ref-type="bibr">54</xref> However, it is also time-consuming, for eg, in one report using cats, although hyperglycemia was induced quickly, within 1&#x02013;2 weeks after the surgery, DR and formation of microaneurysms was observed only after around 5 years.<xref rid="b47-dddt-8-2311" ref-type="bibr">47</xref> Generally, experimental hyperglycemia-inducted methods can be applied in wide types of animals, without obvious species limitation.</p></list-item></list><p>As to the approach of using spontaneously diabetic animals for study of DR, this mainly refers to use of genetic technology to create animals that develop hyperglycemia and diabetes mellitus spontaneously, followed by the development of the pathological changes of DR. The spontaneous DR model has been established using mice, rats, and zebrafish. The DR animal created under this method shares the advantage of consistent phenotypes and high successful rate of induction. However, higher cost and genetic technology are needed. In addition, compared with experimentally induced-DR methods, spontaneous diabetic animals need a longer period to demonstrate DR. There are a relatively small number of animals with special strains that can develop diabetes spontaneously, but this has been reported in rats and monkeys (<xref ref-type="table" rid="t2-dddt-8-2311">Table 2</xref>). Similarly, these animals with intraspecies variation also need a longer period to demonstrate DR, while the phenotypic variation is larger than for genetically mutated animals.</p><p>As to the method of retinal angiogenesis-induction, this refers to inducing retinal blood vessel proliferation without elevation of the blood glucose. The popular methods include oxygen-induced retinopathy and VEGF ocular delivery. Currently, the oxygen-induced retinopathy method is standardized and popularly applied in mice<xref rid="b55-dddt-8-2311" ref-type="bibr">55</xref> and rats,<xref rid="b56-dddt-8-2311" ref-type="bibr">56</xref> while the method of VEGF ocular delivery is more suitable for larger animals, for eg, rabbit and monkey.<xref rid="b57-dddt-8-2311" ref-type="bibr">57</xref> Technically, these are not specific DR models, since they share phenotypes with other retinal neovascular diseases, such as retinopathy of prematurity, retinal vein occlusion, and retinal artery occlusion. However, from the view of pathogenesis, neovascularization is the same key pathogenesis in PDR. In addition, the angiogenic method can induce advanced vascular proliferation to mimic PDR, while the hyperglycemia-induced models mostly mimic NPDR. We summarized the rationale, advantages, and limitations for each popular modeling approach currently used in DR in <xref ref-type="table" rid="t1-dddt-8-2311">Table 1</xref>.</p></sec><sec><title>Animal choices in vivo and cell culture choices in vitro</title><p>Genetically, mouse and zebrafish have the greatest potential as in vivo animal models of DR for the investigation of mechanisms and preclinical drug screening. They have advantages such as similar gene background to humans and ease of manipulation by the current genetic technology. In addition, the small size of animal is also easy to handle and house, and the short lifespan and large breeding rate can shorten the experimental period. These types of animals are inexpensive themselves, although gene modification enhances their cost. However, with the maturation of gene technology, more and more commercial gene-modified animals have already been made available for purchase for achieving different experimental goals with a not very high price. Detailed description of the characteristics of these genetic animals is beyond the purpose in this review; we listed the related references in <xref ref-type="table" rid="t2-dddt-8-2311">Table 2</xref>. In addition, double-gene transgenic or fluorescent gene-added animals extend our understanding and deepen our investigation of the molecular nature of human diseases. These are unique advantages when compared with other animal models.<xref rid="b58-dddt-8-2311" ref-type="bibr">58</xref>&#x02013;<xref rid="b62-dddt-8-2311" ref-type="bibr">62</xref></p><p>Experimentally, mice and rats are still the most popular models of DR, not only because of the advantages mentioned above, but also since there have been many standardized protocols of modeling approaches available for reference to researchers, such as the STZ-injection model, oxygen-induced retinopathy model, and genetic model. In addition, rodents are suitable for the vast majority of detection reagents used in the laboratory. Monkey models share the most similar features of human DR compared with other animal models, which could be applied in research fields like live imaging examinations, diagnosing biomarker screening, and medical or surgical therapeutic trials; however, the approaches for monkeys are far from mature when compared with those for rodents. In addition, the large size, long lifespan, and inevitable ethical requirements have largely limited their applications. Other large animals, like cats and dogs, have large-sized eye balls, which are more convenient for handling than rodent eyes. However, their gene backgrounds are far from human, the number of suitable experimental reagents is far less than for rodents, and their large size needs more housing space, which all limited their usage as the choice of animal models for DR. However, compared with all the above species of animals, the zebrafish has its own advantages as a potential DR model, for eg, the experimental methods of STZ injection,<xref rid="b63-dddt-8-2311" ref-type="bibr">63</xref> high-glucose diet feeding,<xref rid="b52-dddt-8-2311" ref-type="bibr">52</xref> and hypoxia-induced retinopathy (HIR)<xref rid="b64-dddt-8-2311" ref-type="bibr">64</xref> are all convenient to perform in zebrafish, and the zebrafish with the gene <italic>vhl</italic><sup>&#x02212;/&#x02212;</sup> mutation is a spontaneous VEGF-overexpressing animal model, which makes it suitable to mimic the development of PDR<xref rid="b62-dddt-8-2311" ref-type="bibr">62</xref>. However, the less similar retinal vascular structure to human, difficult handling, because of tiny size, and lack of reagents for molecular studies still limit its usage.</p><p>Compared with the in vivo animal model, in vitro culture systems can be used as experimental models of retinal angiogenesis. Since pathological angiogenesis of the retina is the key cause of progression in PDR, the retinal angiogenesis assay is suitable for screening novel antiangiogenic drugs before testing in vivo animals and in patients clinically. In this area, study about various VEGF blockers is the most important direction in recent years. Several generations have been updated, and some of them have been applied clinically to patients, for eg, pegaptanib, ranibizumab, aflibercept, and bevacizumab.<xref rid="b65-dddt-8-2311" ref-type="bibr">65</xref>,<xref rid="b66-dddt-8-2311" ref-type="bibr">66</xref></p><p>Currently, there are two main kinds of in vitro culture proposals. Traditional in vitro cell culture uses isolated endothelial cells or pericytes, in particular, to maximally mimic the human angiogenic process; human-source endothelial cells and pericytes can be used more conveniently than in vivo study. Moreover, retina-derived endothelial cells can be applied<xref rid="b67-dddt-8-2311" ref-type="bibr">67</xref> for the search of specific inhibitors of retinal neovascularization. However, the traditional in vitro culture has its weakness since without the microenvironment of retina, isolated cells may possibly lose their responses to angiogenic molecules. Thus, another culture proposal has been created, which is the ex vivo retinal model. The ex vivo model is established with retinal culture. In PDR, isolating the retina from the in vivo DR model for culture in vitro can be useful for studying the role of proangiogenic factors or antiangiogenic factors in the development of retinal neovascularization.<xref rid="b23-dddt-8-2311" ref-type="bibr">23</xref>,<xref rid="b25-dddt-8-2311" ref-type="bibr">25</xref>,<xref rid="b68-dddt-8-2311" ref-type="bibr">68</xref>,<xref rid="b69-dddt-8-2311" ref-type="bibr">69</xref> We summarized the popular methods applied in common modeling animals and culture systems in <xref ref-type="table" rid="t2-dddt-8-2311">Table 2</xref>.</p></sec></sec><sec><title>Conclusion</title><p>The experimental model is the link between basic and clinical research. It deepens our understanding of the mechanisms and supports us in discovering novel therapeutic interventions to prevent the progression of DR. However, each DR model has its own advantages and limitations. Careful consideration in choosing the model helps us achieve the research goal with high efficiency. The preclinical modeling experiments are ultimately beneficial to clinical patients.</p></sec></body><back><ack><title>Acknowledgments</title><p>Our study was supported by the Natural Science Foundation of People&#x02019;s Republic of China 2013 (grant number 81300766), the National Program on Key Basic Research Project of China (973 Program grant number 2011CB707501), the Cultivation and Innovation Fund from Jinan University (grant number 21613311), and the Cultivation and Innovation Fund from the First Affiliated Hospital of Jinan University (grant number 2013203).</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-dddt-8-2311"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romero-Aroca</surname><given-names>P</given-names></name><name><surname>Sagarra-Alamo</surname><given-names>R</given-names></name><name><surname>Basora-Gallisa</surname><given-names>J</given-names></name><name><surname>Basora-Gallisa</surname><given-names>T</given-names></name><name><surname>Baget-Bernaldiz</surname><given-names>M</given-names></name><name><surname>Bautista-Perez</surname><given-names>A</given-names></name></person-group><article-title>Prospective comparison of two methods of screening for diabetic retinopathy by nonmydriatic fundus camera</article-title><source>Clin Ophthalmol</source><year>2010</year><volume>4</volume><fpage>1481</fpage><lpage>1488</lpage><pub-id pub-id-type="pmid">21191444</pub-id></element-citation></ref><ref id="b2-dddt-8-2311"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>AK</given-names></name><name><surname>Lo</surname><given-names>AC</given-names></name></person-group><article-title>Animal models of diabetic retinopathy: summary and comparison</article-title><source>J Diabetes Res</source><year>2013</year><volume>2013</volume><fpage>106594</fpage><pub-id pub-id-type="pmid">24286086</pub-id></element-citation></ref><ref id="b3-dddt-8-2311"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chhetri</surname><given-names>J</given-names></name><name><surname>Jacobson</surname><given-names>G</given-names></name><name><surname>Gueven</surname><given-names>N</given-names></name></person-group><article-title>Zebrafish &#x02013; on the move towards ophthalmological research</article-title><source>Eye (Lond)</source><year>2014</year><volume>28</volume><issue>4</issue><fpage>367</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">24503724</pub-id></element-citation></ref><ref id="b4-dddt-8-2311"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Rollins</surname><given-names>S</given-names></name><name><surname>Fawzi</surname><given-names>AA</given-names></name></person-group><article-title>Role of endothelial cell and pericyte dysfunction in diabetic retinopathy: review of techniques in rodent models</article-title><source>Adv Exp Med Biol</source><year>2014</year><volume>801</volume><fpage>669</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">24664757</pub-id></element-citation></ref><ref id="b5-dddt-8-2311"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>DH</given-names></name><name><surname>Cho</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Jun</surname><given-names>HO</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Animal models of diabetic retinopathy: doors to investigate pathogenesis and potential therapeutics</article-title><source>J Biomed Sci</source><year>2013</year><volume>20</volume><fpage>38</fpage><pub-id pub-id-type="pmid">23786217</pub-id></element-citation></ref><ref id="b6-dddt-8-2311"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirmiran</surname><given-names>P</given-names></name><name><surname>Bahadoran</surname><given-names>Z</given-names></name><name><surname>Azizi</surname><given-names>F</given-names></name></person-group><article-title>Functional foods-based diet as a novel dietary approach for management of type 2 diabetes and its complications: A review</article-title><source>World J Diabetes</source><year>2014</year><volume>5</volume><issue>3</issue><fpage>267</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">24936248</pub-id></element-citation></ref><ref id="b7-dddt-8-2311"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minhas</surname><given-names>G</given-names></name><name><surname>Morishita</surname><given-names>R</given-names></name><name><surname>Anand</surname><given-names>A</given-names></name></person-group><article-title>Preclinical models to investigate retinal ischemia: advances and drawbacks</article-title><source>Front Neurol</source><year>2012</year><volume>3</volume><fpage>75</fpage><pub-id pub-id-type="pmid">22593752</pub-id></element-citation></ref><ref id="b8-dddt-8-2311"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezzola</surname><given-names>S</given-names></name><name><surname>Belleri</surname><given-names>M</given-names></name><name><surname>Gariano</surname><given-names>G</given-names></name><etal/></person-group><article-title>In vitro and ex vivo retina angiogenesis assays</article-title><source>Angiogenesis</source><year>2014</year><volume>17</volume><issue>3</issue><fpage>429</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">24121991</pub-id></element-citation></ref><ref id="b9-dddt-8-2311"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stitt</surname><given-names>AW</given-names></name><name><surname>Lois</surname><given-names>N</given-names></name><name><surname>Medina</surname><given-names>RJ</given-names></name><name><surname>Adamson</surname><given-names>P</given-names></name><name><surname>Curtis</surname><given-names>TM</given-names></name></person-group><article-title>Advances in our understanding of diabetic retinopathy</article-title><source>Clin Sci (Lond)</source><year>2013</year><volume>125</volume><issue>1</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">23485060</pub-id></element-citation></ref><ref id="b10-dddt-8-2311"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comyn</surname><given-names>O</given-names></name><name><surname>Sivaprasad</surname><given-names>S</given-names></name><name><surname>Peto</surname><given-names>T</given-names></name><etal/></person-group><article-title>A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study)</article-title><source>Am J Ophthalmol</source><year>2014</year><volume>157</volume><issue>5</issue><fpage>960</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">24531025</pub-id></element-citation></ref><ref id="b11-dddt-8-2311"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>JY</given-names></name><name><surname>Byeon</surname><given-names>SH</given-names></name><name><surname>Kwon</surname><given-names>OW</given-names></name></person-group><article-title>Optical coherence tomography-guided selective focal laser photocoagulation: a novel laser protocol for diabetic macular edema</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><comment>Epub</comment><year>2014</year><month>7</month><day>15</day></element-citation></ref><ref id="b12-dddt-8-2311"><label>12</label><element-citation publication-type="journal"><article-title>Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><issue>5 Suppl</issue><fpage>S741</fpage><lpage>S756</lpage></element-citation></ref><ref id="b13-dddt-8-2311"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>CP</given-names></name><name><surname>Ferris</surname><given-names>FL</given-names></name><name><surname>Klein</surname><given-names>RE</given-names></name><etal/><collab>Global Diabetic Retinopathy Project Group</collab></person-group><article-title>Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales</article-title><source>Ophthalmology</source><year>2003</year><volume>110</volume><issue>9</issue><fpage>1677</fpage><lpage>1682</lpage><pub-id pub-id-type="pmid">13129861</pub-id></element-citation></ref><ref id="b14-dddt-8-2311"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duong</surname><given-names>TQ</given-names></name></person-group><article-title>Magnetic resonance imaging of the retina: from mice to men</article-title><source>Magn Reson Med</source><year>2014</year><volume>71</volume><issue>4</issue><fpage>1526</fpage><lpage>1530</lpage><pub-id pub-id-type="pmid">23716429</pub-id></element-citation></ref><ref id="b15-dddt-8-2311"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krasnicki</surname><given-names>P</given-names></name><name><surname>Dmuchowska</surname><given-names>DA</given-names></name><name><surname>Proniewska-Skretek</surname><given-names>E</given-names></name><name><surname>Dobrzycki</surname><given-names>S</given-names></name><name><surname>Mariak</surname><given-names>Z</given-names></name></person-group><article-title>Ocular haemodynamics in patients with type 2 diabetes and coronary artery disease</article-title><source>Br J Ophthalmol</source><year>2014</year><volume>98</volume><issue>5</issue><fpage>675</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">24457359</pub-id></element-citation></ref><ref id="b16-dddt-8-2311"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>SE</given-names></name><name><surname>Loprinzi</surname><given-names>PD</given-names></name></person-group><article-title>Influence of flavonoid-rich fruit and vegetable intake on diabetic retinopathy and diabetes-related biomarkers</article-title><source>J Diabetes Complications</source><comment>Epub</comment><year>2014</year><month>6</month><day>21</day></element-citation></ref><ref id="b17-dddt-8-2311"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>KR</given-names></name><name><surname>Goel</surname><given-names>R</given-names></name><name><surname>Subbannayya</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Proteomic analysis of human vitreous humor</article-title><source>Clin Proteomics</source><year>2014</year><volume>11</volume><issue>1</issue><fpage>29</fpage><pub-id pub-id-type="pmid">25097467</pub-id></element-citation></ref><ref id="b18-dddt-8-2311"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000e9;gnier</surname><given-names>S</given-names></name><name><surname>Malcolm</surname><given-names>W</given-names></name><name><surname>Allen</surname><given-names>F</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Bezlyak</surname><given-names>V</given-names></name></person-group><article-title>Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>7</issue><fpage>e102309</fpage><pub-id pub-id-type="pmid">25029255</pub-id></element-citation></ref><ref id="b19-dddt-8-2311"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bressler</surname><given-names>SB</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Melia</surname><given-names>M</given-names></name><etal/><collab>Diabetic Retinopathy Clinical Research Network</collab></person-group><article-title>Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial</article-title><source>JAMA Ophthalmol</source><year>2013</year><volume>131</volume><issue>8</issue><fpage>1033</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">23807371</pub-id></element-citation></ref><ref id="b20-dddt-8-2311"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewan</surname><given-names>V</given-names></name><name><surname>Lambert</surname><given-names>D</given-names></name><name><surname>Edler</surname><given-names>J</given-names></name><name><surname>Kymes</surname><given-names>S</given-names></name><name><surname>Apte</surname><given-names>RS</given-names></name></person-group><article-title>Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema</article-title><source>Ophthalmology</source><year>2012</year><volume>119</volume><issue>8</issue><fpage>1679</fpage><lpage>1684</lpage><pub-id pub-id-type="pmid">22503301</pub-id></element-citation></ref><ref id="b21-dddt-8-2311"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>AH</given-names></name><name><surname>Lai</surname><given-names>TY</given-names></name></person-group><article-title>Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema</article-title><source>Clin Interv Aging</source><year>2013</year><volume>8</volume><fpage>467</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">23766636</pub-id></element-citation></ref><ref id="b22-dddt-8-2311"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>CL</given-names></name><name><surname>O&#x02019;Doherty</surname><given-names>MT</given-names></name><name><surname>Wilson</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Therapeutic revascularisation of ischaemic tissue: the opportunities and challenges for therapy using vascular stem/progenitor cells</article-title><source>Stem Cell Res Ther</source><year>2012</year><volume>3</volume><issue>4</issue><fpage>31</fpage><pub-id pub-id-type="pmid">22897941</pub-id></element-citation></ref><ref id="b23-dddt-8-2311"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chantelau</surname><given-names>E</given-names></name><name><surname>Meyer-Schwickerath</surname><given-names>R</given-names></name><name><surname>Klabe</surname><given-names>K</given-names></name></person-group><article-title>Downregulation of serum IGF-1 for treatment of early worsening of diabetic retinopathy: a long-term follow-up of two cases</article-title><source>Ophthalmologica</source><year>2010</year><volume>224</volume><issue>4</issue><fpage>243</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">19940532</pub-id></element-citation></ref><ref id="b24-dddt-8-2311"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Schreiter</surname><given-names>K</given-names></name><etal/></person-group><article-title>Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia</article-title><source>Acta Diabetol</source><year>2010</year><volume>47</volume><issue>1</issue><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19238311</pub-id></element-citation></ref><ref id="b25-dddt-8-2311"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim&#x000f3;</surname><given-names>R</given-names></name><name><surname>Carrasco</surname><given-names>E</given-names></name><name><surname>Garc&#x000ed;a-Ramirez</surname><given-names>M</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>C</given-names></name></person-group><article-title>Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy</article-title><source>Current Diabetes Rev</source><year>2006</year><volume>2</volume><issue>1</issue><fpage>71</fpage><lpage>98</lpage></element-citation></ref><ref id="b26-dddt-8-2311"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nebbioso</surname><given-names>M</given-names></name><name><surname>Pranno</surname><given-names>F</given-names></name><name><surname>Pescosolido</surname><given-names>N</given-names></name></person-group><article-title>Lipoic acid in animal models and clinical use in diabetic retinopathy</article-title><source>Expert Opin Pharmacother</source><year>2013</year><volume>14</volume><issue>13</issue><fpage>1829</fpage><lpage>1838</lpage><pub-id pub-id-type="pmid">23790257</pub-id></element-citation></ref><ref id="b27-dddt-8-2311"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nebbioso</surname><given-names>M</given-names></name><name><surname>Federici</surname><given-names>M</given-names></name><name><surname>Rusciano</surname><given-names>D</given-names></name><name><surname>Evangelista</surname><given-names>M</given-names></name><name><surname>Pescosolido</surname><given-names>N</given-names></name></person-group><article-title>Oxidative stress in preretinopathic diabetes subjects and antioxidants</article-title><source>Diabetes Technol Ther</source><year>2012</year><volume>14</volume><issue>3</issue><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">22044044</pub-id></element-citation></ref><ref id="b28-dddt-8-2311"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutoh</surname><given-names>T</given-names></name><name><surname>Kadoya</surname><given-names>K</given-names></name><name><surname>Chikuda</surname><given-names>M</given-names></name></person-group><article-title>Four cases of endophthalmitis after 25-gauge pars plana vitrectomy</article-title><source>Clin Ophthalmol</source><year>2012</year><volume>6</volume><fpage>1393</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">22969284</pub-id></element-citation></ref><ref id="b29-dddt-8-2311"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Berrocal</surname><given-names>MH</given-names></name><name><surname>Ar&#x000e9;valo</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Endophthalmitis after pars plana vitrectomy: results of the Pan American Collaborative Retina Study Group</article-title><source>Retina</source><year>2011</year><volume>31</volume><issue>4</issue><fpage>673</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">21394065</pub-id></element-citation></ref><ref id="b30-dddt-8-2311"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Busch</surname><given-names>S</given-names></name><name><surname>Gretz</surname><given-names>N</given-names></name><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Hammes</surname><given-names>HP</given-names></name></person-group><article-title>Crosstalk in the retinal neurovascular unit &#x02013; lessons for the diabetic retina</article-title><source>Exp Clin Endocrinol Diabetes</source><year>2012</year><volume>120</volume><issue>4</issue><fpage>199</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">22402950</pub-id></element-citation></ref><ref id="b31-dddt-8-2311"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>TA</given-names></name><name><surname>Archer</surname><given-names>DB</given-names></name><name><surname>Curtis</surname><given-names>TM</given-names></name><name><surname>Stitt</surname><given-names>AW</given-names></name></person-group><article-title>Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis</article-title><source>Microcirculation</source><year>2007</year><volume>14</volume><issue>1</issue><fpage>25</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">17365659</pub-id></element-citation></ref><ref id="b32-dddt-8-2311"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stitt</surname><given-names>AW</given-names></name><name><surname>Gardiner</surname><given-names>TA</given-names></name><name><surname>Archer</surname><given-names>DB</given-names></name></person-group><article-title>Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients</article-title><source>Br J Ophthalmol</source><year>1995</year><volume>79</volume><issue>4</issue><fpage>362</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">7742285</pub-id></element-citation></ref><ref id="b33-dddt-8-2311"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bresnick</surname><given-names>GH</given-names></name><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Myers</surname><given-names>FL</given-names></name><name><surname>de Venecia</surname><given-names>G</given-names></name></person-group><article-title>Clinicopathologic correlations in diabetic retinopathy. II. Clinical and histologic appearances of retinal capillary microaneurysms</article-title><source>Arch Ophthalmol</source><year>1977</year><volume>95</volume><issue>7</issue><fpage>1215</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">880082</pub-id></element-citation></ref><ref id="b34-dddt-8-2311"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muir</surname><given-names>ER</given-names></name><name><surname>Renter&#x000ed;a</surname><given-names>RC</given-names></name><name><surname>Duong</surname><given-names>TQ</given-names></name></person-group><article-title>Reduced ocular blood flow as an early indicator of diabetic retinopathy in a mouse model of diabetes</article-title><source>Invest Ophthalmol Vis Sci</source><year>2012</year><volume>53</volume><issue>10</issue><fpage>6488</fpage><lpage>6494</lpage><pub-id pub-id-type="pmid">22915034</pub-id></element-citation></ref><ref id="b35-dddt-8-2311"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das Evcimen</surname><given-names>N</given-names></name><name><surname>King</surname><given-names>GL</given-names></name></person-group><article-title>The role of protein kinase C activation and the vascular complications of diabetes</article-title><source>Pharmacol Res</source><year>2007</year><volume>55</volume><issue>6</issue><fpage>498</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">17574431</pub-id></element-citation></ref><ref id="b36-dddt-8-2311"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>N</given-names></name><name><surname>Komori</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><etal/></person-group><article-title>Assessment of macular function of glaucomatous eyes by multifocal electroretinograms</article-title><source>Doc Ophthalmol</source><comment>Epub</comment><year>2012</year><month>9</month><day>4</day></element-citation></ref><ref id="b37-dddt-8-2311"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>T</given-names></name><name><surname>Cortese</surname><given-names>F</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Westall</surname><given-names>C</given-names></name></person-group><article-title>Analysis of multifocal electroretinograms from a population with type 1 diabetes using partial least squares reveals spatial and temporal distribution of changes to retinal function</article-title><source>Doc Ophthalmol</source><year>2012</year><volume>125</volume><issue>1</issue><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">22610144</pub-id></element-citation></ref><ref id="b38-dddt-8-2311"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casini</surname><given-names>G</given-names></name><name><surname>Dal Monte</surname><given-names>M</given-names></name><name><surname>Fornaciari</surname><given-names>I</given-names></name><name><surname>Filippi</surname><given-names>L</given-names></name><name><surname>Bagnoli</surname><given-names>P</given-names></name></person-group><article-title>The &#x003b2;-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases</article-title><source>Prog Retin Eye Res</source><year>2014</year><volume>42C</volume><fpage>103</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">24933041</pub-id></element-citation></ref><ref id="b39-dddt-8-2311"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuenca</surname><given-names>N</given-names></name><name><surname>Fernandez-S&#x000e1;nchez</surname><given-names>L</given-names></name><name><surname>Campello</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases</article-title><source>Prog Retin Eye Res</source><comment>Epub</comment><year>2014</year><month>7</month><day>17</day></element-citation></ref><ref id="b40-dddt-8-2311"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Kern</surname><given-names>TS</given-names></name></person-group><article-title>Inflammation in diabetic retinopathy</article-title><source>Prog Retin Eye Res</source><year>2011</year><volume>30</volume><issue>5</issue><fpage>343</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">21635964</pub-id></element-citation></ref><ref id="b41-dddt-8-2311"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feit-Leichman</surname><given-names>RA</given-names></name><name><surname>Kinouchi</surname><given-names>R</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes</article-title><source>Invest Ophthalmol Vis Sci</source><year>2005</year><volume>46</volume><issue>11</issue><fpage>4281</fpage><lpage>4287</lpage><pub-id pub-id-type="pmid">16249509</pub-id></element-citation></ref><ref id="b42-dddt-8-2311"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Zhuo</surname><given-names>L</given-names></name></person-group><article-title>Longitudinal in vivo imaging of retinal gliosis in a diabetic mouse model</article-title><source>Exp Eye Res</source><year>2010</year><volume>91</volume><issue>4</issue><fpage>530</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">20655908</pub-id></element-citation></ref><ref id="b43-dddt-8-2311"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yadav</surname><given-names>AS</given-names></name><name><surname>Leskova</surname><given-names>W</given-names></name><name><surname>Harris</surname><given-names>NR</given-names></name></person-group><article-title>Attenuation of streptozotocin-induced microvascular changes in the mouse retina with the endothelin receptor A antagonist atrasentan</article-title><source>Exp Eye Res</source><year>2010</year><volume>91</volume><issue>5</issue><fpage>670</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">20727883</pub-id></element-citation></ref><ref id="b44-dddt-8-2311"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yadav</surname><given-names>AS</given-names></name><name><surname>Leskova</surname><given-names>W</given-names></name><name><surname>Harris</surname><given-names>NR</given-names></name></person-group><article-title>Inhibition of 20-HETE attenuates diabetes-induced decreases in retinal hemodynamics</article-title><source>Exp Eye Res</source><year>2011</year><volume>93</volume><issue>1</issue><fpage>108</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">21658386</pub-id></element-citation></ref><ref id="b45-dddt-8-2311"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>WS</given-names></name><name><surname>Messina</surname><given-names>JE</given-names></name><name><surname>Harris</surname><given-names>NR</given-names></name></person-group><article-title>Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist</article-title><source>Exp Eye Res</source><year>2009</year><volume>88</volume><issue>1</issue><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">18996116</pub-id></element-citation></ref><ref id="b46-dddt-8-2311"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaucher</surname><given-names>D</given-names></name><name><surname>Chiappore</surname><given-names>JA</given-names></name><name><surname>P&#x000e2;ques</surname><given-names>M</given-names></name><etal/></person-group><article-title>Microglial changes occur without neural cell death in diabetic retinopathy</article-title><source>Vision Res</source><year>2007</year><volume>47</volume><issue>5</issue><fpage>612</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">17267004</pub-id></element-citation></ref><ref id="b47-dddt-8-2311"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sennello</surname><given-names>KA</given-names></name><name><surname>Schulman</surname><given-names>RL</given-names></name><name><surname>Prosek</surname><given-names>R</given-names></name><name><surname>Siegel</surname><given-names>AM</given-names></name></person-group><article-title>Systolic blood pressure in cats with diabetes mellitus</article-title><source>J Am Vet Med Assoc</source><year>2003</year><volume>223</volume><issue>2</issue><fpage>198</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">12875445</pub-id></element-citation></ref><ref id="b48-dddt-8-2311"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brosius</surname><given-names>FC</given-names><suffix>3rd</suffix></name><name><surname>Alpers</surname><given-names>CE</given-names></name><name><surname>Bottinger</surname><given-names>EP</given-names></name><etal/><collab>Animal Models of Diabetic Complications Consortium</collab></person-group><article-title>Mouse models of diabetic nephropathy</article-title><source>J Am Soc Nephrol</source><year>2009</year><volume>20</volume><issue>12</issue><fpage>2503</fpage><lpage>2512</lpage><pub-id pub-id-type="pmid">19729434</pub-id></element-citation></ref><ref id="b49-dddt-8-2311"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amemiya</surname><given-names>T</given-names></name><name><surname>Bhutto</surname><given-names>IA</given-names></name></person-group><article-title>Retinal vascular changes and systemic diseases: corrosion cast demonstration</article-title><source>Ital J Anat Embryol</source><year>2001</year><volume>106</volume><issue>2 Suppl 1</issue><fpage>S237</fpage><lpage>S244</lpage></element-citation></ref><ref id="b50-dddt-8-2311"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Bian</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name></person-group><article-title>Tacrolimus (FK506) prevents early retinal neovascularization in streptozotocin-induced diabetic mice</article-title><source>Int Immunopharmacol</source><year>2012</year><volume>14</volume><issue>4</issue><fpage>606</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">23032068</pub-id></element-citation></ref><ref id="b51-dddt-8-2311"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schr&#x000f6;der</surname><given-names>S</given-names></name><name><surname>Palinski</surname><given-names>W</given-names></name><name><surname>Schmid-Sch&#x000f6;nbein</surname><given-names>GW</given-names></name></person-group><article-title>Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy</article-title><source>Am J Pathol</source><year>1991</year><volume>139</volume><issue>1</issue><fpage>81</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">1713023</pub-id></element-citation></ref><ref id="b52-dddt-8-2311"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>TW</given-names></name></person-group><article-title>Glucose intolerance in teleost fish: fact or fiction?</article-title><source>Comp Biochem Physiol B Biochem Mol Biol</source><year>2001</year><volume>129</volume><issue>2&#x02013;3</issue><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">11399456</pub-id></element-citation></ref><ref id="b53-dddt-8-2311"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umazume</surname><given-names>K</given-names></name><name><surname>Barak</surname><given-names>Y</given-names></name><name><surname>McDonald</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Kaplan</surname><given-names>HJ</given-names></name><name><surname>Tamiya</surname><given-names>S</given-names></name></person-group><article-title>Proliferative vitreoretinopathy in the Swine-a new model</article-title><source>Invest Ophthalmol Vis Sci</source><year>2012</year><volume>53</volume><issue>8</issue><fpage>4910</fpage><lpage>4916</lpage><pub-id pub-id-type="pmid">22729438</pub-id></element-citation></ref><ref id="b54-dddt-8-2311"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000fc;chi</surname><given-names>ER</given-names></name><name><surname>Kurosawa</surname><given-names>A</given-names></name><name><surname>Tso</surname><given-names>MO</given-names></name></person-group><article-title>Retinopathy in diabetic hypertensive monkeys: a pathologic study</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>1996</year><volume>234</volume><issue>6</issue><fpage>388</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">8738706</pub-id></element-citation></ref><ref id="b55-dddt-8-2311"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vessey</surname><given-names>KA</given-names></name><name><surname>Wilkinson-Berka</surname><given-names>JL</given-names></name><name><surname>Fletcher</surname><given-names>EL</given-names></name></person-group><article-title>Characterization of retinal function and glial cell response in a mouse model of oxygen-induced retinopathy</article-title><source>J Comp Neurol</source><year>2011</year><volume>519</volume><issue>3</issue><fpage>506</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">21192081</pub-id></element-citation></ref><ref id="b56-dddt-8-2311"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downie</surname><given-names>LE</given-names></name><name><surname>Pianta</surname><given-names>MJ</given-names></name><name><surname>Vingrys</surname><given-names>AJ</given-names></name><name><surname>Wilkinson-Berka</surname><given-names>JL</given-names></name><name><surname>Fletcher</surname><given-names>EL</given-names></name></person-group><article-title>AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy</article-title><source>Glia</source><year>2008</year><volume>56</volume><issue>10</issue><fpage>1076</fpage><lpage>1090</lpage><pub-id pub-id-type="pmid">18442090</pub-id></element-citation></ref><ref id="b57-dddt-8-2311"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Vinores</surname><given-names>SA</given-names></name><name><surname>Moromizato</surname><given-names>Y</given-names></name><name><surname>Campochiaro</surname><given-names>PA</given-names></name><name><surname>Oshima</surname><given-names>K</given-names></name></person-group><article-title>Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates</article-title><source>Exp Eye Res</source><year>1997</year><volume>64</volume><issue>4</issue><fpage>505</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">9227268</pub-id></element-citation></ref><ref id="b58-dddt-8-2311"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Conley</surname><given-names>SM</given-names></name><name><surname>Naash</surname><given-names>MI</given-names></name></person-group><article-title>Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy</article-title><source>Invest Ophthalmol Vis Sci</source><year>2013</year><volume>54</volume><issue>1</issue><fpage>574</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">23221078</pub-id></element-citation></ref><ref id="b59-dddt-8-2311"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dietary wolfberry ameliorates retinal structure abnormalities in db/db mice at the early stage of diabetes</article-title><source>Exp Biol Med (Maywood)</source><year>2011</year><volume>236</volume><issue>9</issue><fpage>1051</fpage><lpage>1063</lpage><pub-id pub-id-type="pmid">21750018</pub-id></element-citation></ref><ref id="b60-dddt-8-2311"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>X</given-names></name><name><surname>Baoyu</surname><given-names>Q</given-names></name><name><surname>Yuzhen</surname><given-names>L</given-names></name><name><surname>Shuli</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>QQ</given-names></name></person-group><article-title>Neuro-optic cell apoptosis and microangiopathy in KKAY mouse retina</article-title><source>Int J Mol Med</source><year>2004</year><volume>13</volume><issue>1</issue><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">14654976</pub-id></element-citation></ref><ref id="b61-dddt-8-2311"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakoczy</surname><given-names>EP</given-names></name><name><surname>Ali Rahman</surname><given-names>IS</given-names></name><name><surname>Binz</surname><given-names>N</given-names></name><etal/></person-group><article-title>Characterization of a mouse model of hyperglycemia and retinal neovascularization</article-title><source>Am J Pathol</source><year>2010</year><volume>177</volume><issue>5</issue><fpage>2659</fpage><lpage>2670</lpage><pub-id pub-id-type="pmid">20829433</pub-id></element-citation></ref><ref id="b62-dddt-8-2311"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rooijen</surname><given-names>E</given-names></name><name><surname>Voest</surname><given-names>EE</given-names></name><name><surname>Logister</surname><given-names>I</given-names></name><etal/></person-group><article-title>von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish</article-title><source>Dis Model Mech</source><year>2010</year><volume>3</volume><issue>5&#x02013;6</issue><fpage>343</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">20335444</pub-id></element-citation></ref><ref id="b63-dddt-8-2311"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>AS</given-names></name><name><surname>Sarras</surname><given-names>MP</given-names><suffix>Jr</suffix></name><name><surname>Intine</surname><given-names>RV</given-names></name></person-group><article-title>Limb regeneration is impaired in an adult zebrafish model of diabetes mellitus</article-title><source>Wound Repair Regen</source><year>2010</year><volume>18</volume><issue>5</issue><fpage>532</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">20840523</pub-id></element-citation></ref><ref id="b64-dddt-8-2311"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Jensen</surname><given-names>LD</given-names></name><name><surname>Rouhi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Hypoxia-induced retinopathy model in adult zebrafish</article-title><source>Nat Protoc</source><year>2010</year><volume>5</volume><issue>12</issue><fpage>1903</fpage><lpage>1910</lpage><pub-id pub-id-type="pmid">21127484</pub-id></element-citation></ref><ref id="b65-dddt-8-2311"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semeraro</surname><given-names>F</given-names></name><name><surname>Morescalchi</surname><given-names>F</given-names></name><name><surname>Duse</surname><given-names>S</given-names></name><name><surname>Gambicorti</surname><given-names>E</given-names></name><name><surname>Romano</surname><given-names>MR</given-names></name><name><surname>Costagliola</surname><given-names>C</given-names></name></person-group><article-title>Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview</article-title><source>Expert Opin Drug Saf</source><year>2014</year><volume>13</volume><issue>6</issue><fpage>785</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">24809388</pub-id></element-citation></ref><ref id="b66-dddt-8-2311"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>MW</given-names></name></person-group><article-title>The expanding role of vascular endothelial growth factor inhibitors in ophthalmology</article-title><source>Mayo Clin Proc</source><year>2012</year><volume>87</volume><issue>1</issue><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">22212972</pub-id></element-citation></ref><ref id="b67-dddt-8-2311"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shima</surname><given-names>DT</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><etal/></person-group><article-title>Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen</article-title><source>Mol Med</source><year>1995</year><volume>1</volume><issue>2</issue><fpage>182</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">8529097</pub-id></element-citation></ref><ref id="b68-dddt-8-2311"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haurigot</surname><given-names>V</given-names></name><name><surname>Villacampa</surname><given-names>P</given-names></name><name><surname>Ribera</surname><given-names>A</given-names></name><etal/></person-group><article-title>Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>7</issue><fpage>e41511</fpage><pub-id pub-id-type="pmid">22911805</pub-id></element-citation></ref><ref id="b69-dddt-8-2311"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitmire</surname><given-names>W</given-names></name><name><surname>Al-Gayyar</surname><given-names>MM</given-names></name><name><surname>Abdelsaid</surname><given-names>M</given-names></name><name><surname>Yousufzai</surname><given-names>BK</given-names></name><name><surname>El-Remessy</surname><given-names>AB</given-names></name></person-group><article-title>Alteration of growth factors and neuronal death in diabetic retinopathy: what we have learned so far</article-title><source>Mol Vis</source><year>2011</year><volume>17</volume><fpage>300</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">21293735</pub-id></element-citation></ref><ref id="b70-dddt-8-2311"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kowluru</surname><given-names>RA</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Kern</surname><given-names>TS</given-names></name></person-group><article-title>Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy</article-title><source>Diabetes</source><year>2001</year><volume>50</volume><issue>8</issue><fpage>1938</fpage><lpage>1942</lpage><pub-id pub-id-type="pmid">11473058</pub-id></element-citation></ref><ref id="b71-dddt-8-2311"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kador</surname><given-names>PF</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Wyman</surname><given-names>M</given-names></name><name><surname>Ferris</surname><given-names>F</given-names></name></person-group><article-title>Diabeteslike proliferative retinal changes in galactose-fed dogs</article-title><source>Arch Ophthalmol</source><year>1995</year><volume>113</volume><issue>3</issue><fpage>352</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">7887849</pub-id></element-citation></ref><ref id="b72-dddt-8-2311"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CR</given-names></name><name><surname>Sun</surname><given-names>SG</given-names></name></person-group><article-title>VEGF expression and cell apoptosis in NOD mouse retina</article-title><source>Int J Ophthalmol</source><year>2010</year><volume>3</volume><issue>3</issue><fpage>224</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">22553559</pub-id></element-citation></ref><ref id="b73-dddt-8-2311"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sima</surname><given-names>AA</given-names></name><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Garcia-Salinas</surname><given-names>R</given-names></name><name><surname>Basu</surname><given-names>PK</given-names></name></person-group><article-title>The BB-rat &#x02013; an authentic model of human diabetic retinopathy</article-title><source>Curr Eye Res</source><year>1985</year><volume>4</volume><issue>10</issue><fpage>1087</fpage><lpage>1092</lpage><pub-id pub-id-type="pmid">4064731</pub-id></element-citation></ref><ref id="b74-dddt-8-2311"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Eeden</surname><given-names>PE</given-names></name><name><surname>Tee</surname><given-names>LB</given-names></name><name><surname>Lukehurst</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><issue>10</issue><fpage>4638</fpage><lpage>4645</lpage><pub-id pub-id-type="pmid">17003462</pub-id></element-citation></ref><ref id="b75-dddt-8-2311"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><issue>2</issue><fpage>732</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">18235022</pub-id></element-citation></ref><ref id="b76-dddt-8-2311"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>YS</given-names></name><name><surname>Danis</surname><given-names>RP</given-names></name><name><surname>Peterson</surname><given-names>RG</given-names></name><name><surname>Dolan</surname><given-names>PL</given-names></name><name><surname>Wu</surname><given-names>YQ</given-names></name></person-group><article-title>Acarbose partially inhibits microvascular retinopathy in the Zucker Diabetic Fatty rat (ZDF/Gmi-fa)</article-title><source>J Ocul Pharmacol Ther</source><year>2000</year><volume>16</volume><issue>5</issue><fpage>471</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">11110039</pub-id></element-citation></ref><ref id="b77-dddt-8-2311"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>ZY</given-names></name><name><surname>Bhutto</surname><given-names>IA</given-names></name><name><surname>Amemiya</surname><given-names>T</given-names></name></person-group><article-title>Retinal changes in Otsuka long-evans Tokushima Fatty rats (spontaneously diabetic rat) &#x02013; possibility of a new experimental model for diabetic retinopathy</article-title><source>Jpn J Ophthalmol</source><year>2003</year><volume>47</volume><issue>1</issue><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12586175</pub-id></element-citation></ref><ref id="b78-dddt-8-2311"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Ogura</surname><given-names>Y</given-names></name><name><surname>Nishiwaki</surname><given-names>H</given-names></name><etal/></person-group><article-title>Evaluation of retinal microcirculatory alterations in the Goto-Kakizaki rat. A spontaneous model of non-insulin-dependent diabetes</article-title><source>Invest Ophthalmol Vis Sci</source><year>1996</year><volume>37</volume><issue>5</issue><fpage>898</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">8603874</pub-id></element-citation></ref><ref id="b79-dddt-8-2311"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>E</given-names></name><name><surname>Higuchi</surname><given-names>A</given-names></name><name><surname>Matsumura</surname><given-names>M</given-names></name></person-group><article-title>Retinal neovascularisation without ischaemia in the spontaneously diabetic Torii rat</article-title><source>Diabetologia</source><year>2005</year><volume>48</volume><issue>8</issue><fpage>1663</fpage><lpage>1668</lpage><pub-id pub-id-type="pmid">15977012</pub-id></element-citation></ref><ref id="b80-dddt-8-2311"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhutto</surname><given-names>IA</given-names></name><name><surname>Miyamura</surname><given-names>N</given-names></name><name><surname>Amemiya</surname><given-names>T</given-names></name></person-group><article-title>Vascular architecture of degenerated retina in WBN/Kob rats: corrosion cast and electron microscopic study</article-title><source>Ophthalmic Res</source><year>1999</year><volume>31</volume><issue>5</issue><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">10420122</pub-id></element-citation></ref><ref id="b81-dddt-8-2311"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drago</surname><given-names>F</given-names></name><name><surname>La Manna</surname><given-names>C</given-names></name><name><surname>Emmi</surname><given-names>I</given-names></name><name><surname>Marino</surname><given-names>A</given-names></name></person-group><article-title>Effects of sulfinpyrazone on retinal damage induced by experimental diabetes mellitus in rabbits</article-title><source>Pharmacol Res</source><year>1998</year><volume>38</volume><issue>2</issue><fpage>97</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">9721595</pub-id></element-citation></ref><ref id="b82-dddt-8-2311"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>TA</given-names></name><name><surname>Stitt</surname><given-names>AW</given-names></name><name><surname>Anderson</surname><given-names>HR</given-names></name><name><surname>Archer</surname><given-names>DB</given-names></name></person-group><article-title>Selective loss of vascular smooth muscle cells in the retinal microcirculation of diabetic dogs</article-title><source>Br J Ophthalmol</source><year>1994</year><volume>78</volume><issue>1</issue><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8110701</pub-id></element-citation></ref><ref id="b83-dddt-8-2311"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Rattigan</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Ultrastructural features of retinal capillary basement membrane thickening in diabetic swine</article-title><source>Ultrastruct Pathol</source><year>2010</year><volume>34</volume><issue>1</issue><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">20070152</pub-id></element-citation></ref><ref id="b84-dddt-8-2311"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Sowers</surname><given-names>S</given-names></name><name><surname>Bagree</surname><given-names>SV</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name></person-group><article-title>Retinal redox stress and remodeling in cardiometabolic syndrome and diabetes</article-title><source>Oxid Med Cell Longev</source><year>2010</year><volume>3</volume><issue>6</issue><fpage>392</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">21307645</pub-id></element-citation></ref><ref id="b85-dddt-8-2311"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Johnson</surname><given-names>MA</given-names></name><name><surname>McLeod</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Retinopathy in monkeys with spontaneous type 2 diabetes</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><issue>12</issue><fpage>4543</fpage><lpage>4553</lpage><pub-id pub-id-type="pmid">15557466</pub-id></element-citation></ref><ref id="b86-dddt-8-2311"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Ruan</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab</article-title><source>Angiogenesis</source><year>2012</year><volume>15</volume><issue>2</issue><fpage>171</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">22302382</pub-id></element-citation></ref><ref id="b87-dddt-8-2311"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huxlin</surname><given-names>KR</given-names></name><name><surname>Sefton</surname><given-names>AJ</given-names></name><name><surname>Schulz</surname><given-names>M</given-names></name><name><surname>Bennett</surname><given-names>MR</given-names></name></person-group><article-title>Effect of proteoglycan purified from rat superior colliculus on the survival of murine retinal ganglion cells</article-title><source>Brain Res Dev Brain Res</source><year>1993</year><volume>74</volume><issue>2</issue><fpage>207</fpage><lpage>217</lpage></element-citation></ref><ref id="b88-dddt-8-2311"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawamiphak</surname><given-names>S</given-names></name><name><surname>Seidel</surname><given-names>S</given-names></name><name><surname>Essmann</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis</article-title><source>Nature</source><year>2010</year><volume>465</volume><issue>7297</issue><fpage>487</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">20445540</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-dddt-8-2311" position="float"><label>Figure 1</label><caption><p>Neurovascular hypothesis for the pathogenesis of diabetic retinopathy.</p><p><bold>Abbreviations:</bold> BM, basement membrane; BRB, blood&#x02013;retinal barrier; NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.</p></caption><graphic xlink:href="dddt-8-2311Fig1"/></fig><table-wrap id="t1-dddt-8-2311" position="float"><label>Table 1</label><caption><p>Comparison of popular methods for modeling of different animals of DR</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Animal</th><th valign="top" align="left" rowspan="1" colspan="1">NPDR</th><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">PDR</th><th valign="top" align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Mouse</td><td valign="top" align="left" rowspan="1" colspan="1">1) STZ injection<xref rid="b41-dddt-8-2311" ref-type="bibr">41</xref>&#x02013;<xref rid="b45-dddt-8-2311" ref-type="bibr">45</xref><break/>2) Alloxan injection<xref rid="b46-dddt-8-2311" ref-type="bibr">46</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Galactose-fed<xref rid="b46-dddt-8-2311" ref-type="bibr">46</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Transgenic/Gene mutated mice: Akita mice;<xref rid="b58-dddt-8-2311" ref-type="bibr">58</xref> NOD mice;<xref rid="b72-dddt-8-2311" ref-type="bibr">72</xref> db/db mice;<xref rid="b59-dddt-8-2311" ref-type="bibr">59</xref> KKAy mice<xref rid="b60-dddt-8-2311" ref-type="bibr">60</xref></td><td valign="top" align="left" rowspan="1" colspan="1">OIR<xref rid="b55-dddt-8-2311" ref-type="bibr">55</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Transgenic/Gene mutated mice: Kimba mice;<xref rid="b74-dddt-8-2311" ref-type="bibr">74</xref> Akimba mice<xref rid="b61-dddt-8-2311" ref-type="bibr">61</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rat</td><td valign="top" align="left" rowspan="1" colspan="1">1) STZ injection<xref rid="b75-dddt-8-2311" ref-type="bibr">75</xref><break/>2) Alloxan injection<xref rid="b51-dddt-8-2311" ref-type="bibr">51</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Galactose-fed<xref rid="b70-dddt-8-2311" ref-type="bibr">70</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Gene/Substrain modified rats: BB rats;<xref rid="b73-dddt-8-2311" ref-type="bibr">73</xref> ZDF rats;<xref rid="b76-dddt-8-2311" ref-type="bibr">76</xref> OLETF rats;<xref rid="b77-dddt-8-2311" ref-type="bibr">77</xref> GK rats;<xref rid="b78-dddt-8-2311" ref-type="bibr">78</xref> SDT rats<xref rid="b79-dddt-8-2311" ref-type="bibr">79</xref></td><td valign="top" align="left" rowspan="1" colspan="1">OIR<xref rid="b56-dddt-8-2311" ref-type="bibr">56</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Gene/Substrain modified rats:WBN/Kob rats<xref rid="b80-dddt-8-2311" ref-type="bibr">80</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Large animals (rabbits, cats, dogs, pigs, monkeys)</td><td valign="top" align="left" rowspan="1" colspan="1">1) STZ injection: rabbits;<xref rid="b81-dddt-8-2311" ref-type="bibr">81</xref> dogs;<xref rid="b82-dddt-8-2311" ref-type="bibr">82</xref> pigs;<xref rid="b83-dddt-8-2311" ref-type="bibr">83</xref> monkeys<xref rid="b54-dddt-8-2311" ref-type="bibr">54</xref><break/>2) Alloxan injection: pigs<xref rid="b84-dddt-8-2311" ref-type="bibr">84</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Galactose-fed: dogs<xref rid="b71-dddt-8-2311" ref-type="bibr">71</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Others:<break/>1) VEGF intravitreal delivery: monkeys<xref rid="b57-dddt-8-2311" ref-type="bibr">57</xref><break/>2) Pancreatectomy: cats;<xref rid="b47-dddt-8-2311" ref-type="bibr">47</xref> pigs;<xref rid="b53-dddt-8-2311" ref-type="bibr">53</xref> monkeys<xref rid="b54-dddt-8-2311" ref-type="bibr">54</xref><break/>3) Spontaneous obese monkeys<xref rid="b85-dddt-8-2311" ref-type="bibr">85</xref></td><td valign="top" align="left" rowspan="1" colspan="1">VEGF intravitreal delivery: rabbits<xref rid="b57-dddt-8-2311" ref-type="bibr">57</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zebrafish</td><td valign="top" align="left" rowspan="1" colspan="1">STZ injection<xref rid="b63-dddt-8-2311" ref-type="bibr">63</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Glucose-fed<xref rid="b52-dddt-8-2311" ref-type="bibr">52</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Transgenic/Gene mutation: <italic>vhl</italic><sup>&#x02212;/&#x02212;</sup> zebrafish<xref rid="b62-dddt-8-2311" ref-type="bibr">62</xref></td><td valign="top" align="left" rowspan="1" colspan="1">HIR<xref rid="b64-dddt-8-2311" ref-type="bibr">64</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">In vitro culture</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">In vitro culture of endothelial cells<xref rid="b86-dddt-8-2311" ref-type="bibr">86</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Ex vivo retinal culture<xref rid="b87-dddt-8-2311" ref-type="bibr">87</xref>,<xref rid="b88-dddt-8-2311" ref-type="bibr">88</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn1-dddt-8-2311"><p><bold>Abbreviations:</bold> DR, diabetic retinopathy; GK, Goto-Kakizaki; HIR, hypoxia-induced retinopathy; NOD, nonobese diabetic; NPDR, nonproliferative diabetic retinopathy; OIR, oxygen-induced retinopathy; OLETF, Otsuka Long-Evans Tokushima fatty; PDR, proliferative diabetic retinopathy; SDT, spontaneously diabetic Torii; STZ, streptozotocin; VEGF, vascular endothelial growth factor; WBN/Kob, Wistar Bonn/Kobori; ZDF, Zucker diabetic fatty.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-dddt-8-2311" position="float"><label>Table 2</label><caption><p>Comparison of rationale, advantages, and limitations of different modeling approaches of DR</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Approach</th><th valign="top" align="left" rowspan="1" colspan="1">Rationale</th><th valign="top" align="left" rowspan="1" colspan="1">Advantages</th><th valign="top" align="left" rowspan="1" colspan="1">Limitations</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">STZ injection<xref rid="b41-dddt-8-2311" ref-type="bibr">41</xref>&#x02013;<xref rid="b45-dddt-8-2311" ref-type="bibr">45</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Destroys pancreas, leading to hyperglycemia</td><td valign="top" align="left" rowspan="1" colspan="1">1) Classic method<break/>2) Fast induction</td><td valign="top" align="left" rowspan="1" colspan="1">1) Need to monitor the blood glucose level to confirm the presence of hyperglycemia<break/>2) Mostly forms NPDR, rarely forms PDR</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Galactose-fed<xref rid="b46-dddt-8-2311" ref-type="bibr">46</xref>,<xref rid="b70-dddt-8-2311" ref-type="bibr">70</xref>,<xref rid="b71-dddt-8-2311" ref-type="bibr">71</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Induces hyperglycemia through diet</td><td valign="top" align="left" rowspan="1" colspan="1">Applicable to zebrafish, when galactose replaced by glucose in fishpond</td><td valign="top" align="left" rowspan="1" colspan="1">1) Need longer period to onset of retinopathy in mammals<break/>2) Mostly forms NPDR, rarely forms PDR</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pancreatectomy<xref rid="b47-dddt-8-2311" ref-type="bibr">47</xref>,<xref rid="b53-dddt-8-2311" ref-type="bibr">53</xref>,<xref rid="b54-dddt-8-2311" ref-type="bibr">54</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Removes pancreas to lose the control of blood glucose by insulin</td><td valign="top" align="left" rowspan="1" colspan="1">Applicable to large animals, like cat and monkey</td><td valign="top" align="left" rowspan="1" colspan="1">1) Large variation among individuals and species<break/>2) Need longer period to onset of retinopathy<break/>3) Mostly forms NPDR, rarely forms PDR</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Transgene/Gene mutation<xref rid="b58-dddt-8-2311" ref-type="bibr">58</xref>,<xref rid="b62-dddt-8-2311" ref-type="bibr">62</xref>,<xref rid="b72-dddt-8-2311" ref-type="bibr">72</xref>,<xref rid="b73-dddt-8-2311" ref-type="bibr">73</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Effect on the spontaneous degeneration of pancreatic &#x003b2; cells</td><td valign="top" align="left" rowspan="1" colspan="1">1) Consistent phenotype<break/>2) High success rate of hyperglycemia</td><td valign="top" align="left" rowspan="1" colspan="1">1) High cost<break/>2) Needs genetic technology<break/>3) Mostly forms NPDR, rarely forms PDR; only Akimba transgenic mice were reported to show PDR formation<xref rid="b61-dddt-8-2311" ref-type="bibr">61</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">OIR<xref rid="b55-dddt-8-2311" ref-type="bibr">55</xref>,<xref rid="b56-dddt-8-2311" ref-type="bibr">56</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Angiogenesis and neovascularization</td><td valign="top" align="left" rowspan="1" colspan="1">1) Definite neovascularization<break/>2) Classic method</td><td valign="top" align="left" rowspan="1" colspan="1">1) Non-DR-specific<break/>2) Applicable to newborn rodents</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ocular delivery of VEGF<xref rid="b57-dddt-8-2311" ref-type="bibr">57</xref></td><td valign="top" align="left" rowspan="1" colspan="1">VEGF-induced angiogenesis</td><td valign="top" align="left" rowspan="1" colspan="1">Theoretically induce neovascularization directly</td><td valign="top" align="left" rowspan="1" colspan="1">1) Non-DR-specific<break/>2) Large variation among individuals and species<break/>3) After metabolized, effects of VEGF disappear<break/>4) Suitable for large animals<xref rid="b57-dddt-8-2311" ref-type="bibr">57</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn2-dddt-8-2311"><p><bold>Abbreviations:</bold> DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; OIR, oxygen-induced retinopathy; PDR, proliferative diabetic retinopathy; STZ, streptozotocin; VEGF, vascular endothelial growth factor.</p></fn></table-wrap-foot></table-wrap></floats-group></article>
